知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.011 秒)

    AMPK ACTIVATORS
    3.
    发明申请
    AMPK ACTIVATORS 有权

    公开(公告)号：US20220033401A1

    公开(公告)日：2022-02-03

    申请号：US17502474

    申请日：2021-10-15

    申请人： Kallyope, Inc.

    发明人： Iyassu SEBHAT ,  Shuwen HE ,  Ann WEBER ,  Nancy THORNBERRY ,  Lisa KRUG ,  Paul RICHARDS ,  Brett LAURING

    IPC分类号： C07D471/04 ,  A61P1/04 ,  A61P1/12

    摘要： This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.

    AMPK ACTIVATORS
    4.
    发明申请
    AMPK ACTIVATORS 有权

    公开(公告)号：US20220227754A1

    公开(公告)日：2022-07-21

    申请号：US17584831

    申请日：2022-01-26

    申请人： Kallyope, Inc.

    发明人： Iyassu SEBHAT ,  Shuwen HE ,  Ann WEBER ,  Nancy THORNBERRY ,  Lisa KRUG ,  Paul RICHARDS ,  Brett LAURING

    IPC分类号： C07D471/04 ,  A61P1/12 ,  A61P1/04

    摘要： This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.

    GPCR COMBINATION THERAPIES
    6.
    发明申请
    GPCR COMBINATION THERAPIES 有权

    公开(公告)号：US20220152164A1

    公开(公告)日：2022-05-19

    申请号：US17440901

    申请日：2020-03-19

    申请人： Kallyope, Inc.

    发明人： Nancy THORNBERRY ,  Ann WEBER ,  Maja ENGELSTOFT ,  Zac FARINO ,  Ian PEIKON ,  Shirly PINTO ,  Iyassu SEBHAT ,  Paul RICHARDS

    IPC分类号： A61K38/48 ,  A61K45/06 ,  A61P3/04

    摘要： This disclosure is directed, at least in part, to GPCR modulators in combination therapies useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, these modulators are gut-restricted compounds. In some embodiments, these modulators are GPCR agonists, antagonists, inverse agonists, neutral antagonists, positive allosteric modulators, or negative allosteric modulators. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes or obesity, or a nutritional disorder such as short bowel syndrome.

    AMPK ACTIVATORS
    7.
    发明申请
    AMPK ACTIVATORS 有权

    公开(公告)号：US20220002317A1

    公开(公告)日：2022-01-06

    申请号：US17358385

    申请日：2021-06-25

    申请人： Kallyope, Inc.

    发明人： Iyassu SEBHAT ,  Shuwen HE

    IPC分类号： C07D519/00 ,  A61P3/10 ,  A61P1/00 ,  C07F9/6561 ,  C07D493/04

    摘要： This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists, super agonists, full agonists, or partial agonists.

    GPR40 AGONISTS
    10.
    发明申请
    GPR40 AGONISTS 有权

    公开(公告)号：US20220289772A1

    公开(公告)日：2022-09-15

    申请号：US17745126

    申请日：2022-05-16

    申请人： Kallyope, Inc.

    发明人： Iyassu SEBHAT ,  Shuwen HE

    IPC分类号： C07F9/38 ,  A61K31/662 ,  A61K31/10 ,  C07C309/24 ,  C07F9/30 ,  C07F9/58 ,  A61K31/675 ,  C07F9/59

    摘要： This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.